418 related articles for article (PubMed ID: 9815853)
1. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
Tan M; Yao J; Yu D
Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
[TBL] [Abstract][Full Text] [Related]
3. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
4. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
5. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
[TBL] [Abstract][Full Text] [Related]
6. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
9. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
10. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
11. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
12. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
[TBL] [Abstract][Full Text] [Related]
13. Differential signaling by an anti-p185(HER2) antibody and heregulin.
Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC
Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064
[TBL] [Abstract][Full Text] [Related]
14. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of adhesion molecules expression by human endothelial cells cocultured with c-erbB2-positive and c-erbB2-negative breast carcinoma cell lines.
Markowska A; Urasińska E; Domagała W
Pol J Pathol; 2008; 59(1):49-54. PubMed ID: 18655371
[TBL] [Abstract][Full Text] [Related]
17. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
[TBL] [Abstract][Full Text] [Related]
18. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
19. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Boente MP; Berchuck A; Whitaker RS; Kalén A; Xu FJ; Clarke-Pearson DL; Bell RM; Bast RC
Gynecol Oncol; 1998 Jul; 70(1):49-55. PubMed ID: 9698473
[TBL] [Abstract][Full Text] [Related]
20. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
